Login to Your Account

Sosei Reports GLOWing Results from Phase III in COPD

By Catherine Shaffer
Staff Writer

Friday, May 18, 2012
Sosei Group Corp. reported that NVA237 beat placebo at improving lung function, symptom relief and quality of life among sufferers of chronic obstructive pulmonary disease (COPD) in its Phase III GLOW2 trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription